Ripertamab
- Generic Name
- Ripertamab
- Drug Type
- Biotech
- CAS Number
- 2249927-04-4
- Unique Ingredient Identifier
- URS0374MIV
Overview
Ripertamab is under investigation in clinical trial NCT02772822 (A Study Comparing the Efficiency and Safety of S-chop(cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated Cd20(cluster of Differentiation Antigen 20)-positive DLBCL Patients).
Background
Ripertamab is under investigation in clinical trial NCT02772822 (A Study Comparing the Efficiency and Safety of S-chop(cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated Cd20(cluster of Differentiation Antigen 20)-positive DLBCL Patients).
Indication
用于国际预后指数（IPI）为0〜2分的新诊断CD20阳性弥漫大B细胞性非霍奇金淋巴瘤（DLBCL）成人患者，应与标准CHOP化疗（环磷酰胺、阿霉素、长春新碱、强的松）联合治疗。
Associated Conditions
No associated conditions information available.
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.